Extracorporeal arteriovenous carbon dioxide removal (AVCO 2 R) using percutaneous cannulae and a low resistance gas exchanger achieves near total CO 2 removal, allowing lung rest and potentially improving survival. AVCO 2 R, redesigned to allow ambulation, has potential as treatment for severe chronic obstructive pulmonary disease or rehabilitation before lung transplant. The purposes of this study were to 1) determine the optimal ambulatory access for AVCO 2 removal and 2) develop a prototype Ambulatory-AVCO 2 R gas exchanger. Initially, reinforced Gore-Tex 6 mm (two) and 8 mm (four) grafts were anastomosed to sheep carotid arteries and jugular veins as a loop in parallel to the cranial circulation to determine blood flow capabilities. Blood flow was 100 -150 ml/min with a 14 gauge dialysis needle, and transected 6 mm Gore-Tex grafts achieved 500 -900 ml blood flow, whereas transected 8 mm grafts achieved up to 2000 ml/min flow. The polytetrafluoroethylene (PTFE) loops were then connected to our newly developed ultra low resistance pumpless gas exchanger for ambulatory AVCO 2 R. The average pressure gradient across the prototype Ambulatory-AVCO 2 R gas exchangers (n ‫؍‬ 5) was 2.8 ؎ 0.8 mm Hg, and mean CO 2 removal was 104.8 ؎ 14.0 ml/min, with an average blood flow of 900 ml/min. We conclude that an 8 mm Gore-Tex reinforced graft arteriovenous loop supplies ample blood flow for our new ultra low resistance Ambulatory-AVCO 2 R to achieve near total CO 2 removal. ASAIO Journal 2003; 49:564 -567.
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Extracorporeal carbon dioxide removal using percutaneous arterial and venous cannulae connected to a membrane oxygenator (arteriovenous CO 2 removal [AVCO 2 R]) is a simplified form of extracorporeal membrane oxygenation (ECMO). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The use of a simple arteriovenous shunt eliminates the roller pump and a substantial portion of tubing and ECMO related components, resulting in reduced foreign surface area, priming fluid, and blood transfusion volume. AVCO 2 R achieves near total CO 2 removal in adults at about 1 L/min of blood flow (Qb). 12, 13 Mean arterial pressure drives flow, precluding the need for an external pump and allowing AVCO 2 R to be potentially ambulatory. During AVCO 2 R, CO 2 removal and O 2 transfer are uncoupled. CO 2 is transferred across the gas exchanger, whereas the vast majority of oxygen diffusion occurs across the native lungs, a process called apneic oxygenation, or during low frequency positive pressure ventilation. 14 AVCO 2 R appears to be very effective for early onset acute respiratory distress syndrome (ARDS) as shown in prospective, randomized, unblinded large-animal studies and preliminary clinical trials. 10 -13 During end-stage chronic obstructive pulmonary disease (COPD), the work of breathing becomes prohibitive, and CO 2 retention, not oxygenation, characterizes the disease. AVCO 2 R, with its unique uncoupling of CO 2 removal from oxygenation, is well suited to treat end-stage COPD. Our goal is to develop ambulatory AVCO 2 R as a management technique for severe COPD to facilitate ambulation and rehabilitation and thus to enhance suitability for lung transplant or recovery from an acute exacerbation of the disease.
To date, animal and human AVCO 2 R studies have used percutaneous cannula insertion. Percutaneous cannulae are unsuitable for long-term or ambulatory use because of the potential for pericannula thrombosis and leak, cannula dislodgement, and cannula trauma to the vessel intima during limb motion. A solution for ambulation and longer-term application is an arteriovenous prosthetic graft similar to that used with chronic hemodialysis. Our experimental design is divided into two parts: 1) determine flow characteristics of different types of arteriovenous loop access and 2) determine initial performance of a prototype Ambulatory-AVCO 2 R gas exchange device using the best-flow arteriovenous loops.
Materials and Methods
All animals received humane care according to the Guide for the Care and Use of Laboratory Animals (1996) prepared by the United States Department of Health and Human Services and published by the National Institutes of Health. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of The University of Texas Medical Branch, Galveston, Texas, with strict adherence to the IACUC guidelines regarding humane use of animals. Our management of the sheep parallels our standards of patient care. An investigator is present to outline and supervise management. Our team also consists of a full-time staff veterinary anesthesiologist (DJD) who oversees all anesthesia, sedation and animal management issues. IACUC personnel, with no conflicts of interest, make daily rounds to check compliance with the animal management protocol.
Adult sheep (22-46 kg) were anesthetized, orotracheally intubated, and systemically anticoagulated (300 IU/kg bovine lung heparin, Upjohn, Kalamazoo, MI). Femoral arterial and thermodilution pulmonary artery catheters were placed by open cut-down. Animals then underwent placement of an arteriovenous shunt to the left carotid artery and the left jugular vein.
Arteriovenous Loop Flow Studies
Ring-reinforced polytetrafluoroethylene (PTFE) loops of 6 mm (n ϭ 2) and 8 mm (n ϭ 3) diameter were anastomosed end of graft to the side of the carotid artery and jugular vein with 6 -0 polypropylene then tunneled to exit the skin for acute flow studies. Access was provided to the arteriovenous loop, in sequence, by 1) two 14 G dialysis needles, 2) 12 and 14 F arterial and venous cannulae placed into the graft but short of the arterial anastomosis, 3) the same arterial cannula advanced past the arterial-PTFE anastomosis directly into the artery facing upstream, and, finally, 4) by transecting the PTFE graft and connecting it end on to the gas exchange device.
Ambulatory-AVCO 2 R Prototype
Blood enters the device by way of a 1/4 inch inlet connector in the center of the fiber bundle, flows radially through evenly spaced, parallel-wound fibers, and then flows out two tangentially placed, symmetric outlets which taper from 3/8 to 1/4 inches (Figure 1) . The outlets are then brought together by way of a Y-connector before attachment to the graft material. The surface area of the Ambulatory-AVCO 2 R device is 2 m 2 . The dual outlet design is used to promote uniform perfusion of the fiber bundle. The device was designed and fabricated at MC3 Corp, Ann Arbor, MI. The housing and components were fabricated out of medical grade acrylonitrile butadiene styrene (ABS) using a rapid prototyping machine (FDM 2000, Stratasys Inc., Eden Prairie, MN). The fiber bundle consists of an X30 -240 polypropylene fiber mat (50 fibers/inch, Celgard Inc., Charlotte, NC) that was hand wound around a Teflon mandrel. The fibers are potted into the housing using a centrifuge that uniformly spreads the potting resin (F70 A/B polyurethane, BJB Enterprises, Tustin, CA) around the hollow fibers. The potting caps are machined from ultrahigh molecular weight polyethylene (UHMWPE) in house. After potting, the Teflon mandrel is removed, leaving the centrally located inner core.
In the Ambulatory-AVCO 2 R prototype study (n ϭ 5), the sheep remained systemically anticoagulated with an intravenous infusion of heparin titrated to keep activated coagulation time (ACT) at 200 -300 seconds. A tracheostomy was then placed. An 8 cm ring-reinforced PTFE loop was used, as was a C clamp tightened to restrict Qb to 900 -1000 ml/min. Sweep gas (100% O 2 ) remained constant at 2 L/min. Spontaneous breathing was suppressed with pentobarbital to allow CO 2 to increase to 40 -45 mm Hg. Ventilator settings were as follows: respiratory rate 4 breaths/minute, tidal volume 10 ml/kg, and FiO 2 was 100 -80 to keep PaO 2 greater than 100 mm Hg.
Qb was monitored using an ultrasonic flow probe (Model H6X, Transonic Systems, Ithaca, NY) placed on the arterial cannula and interfaced with a real-time flow meter (Model HT 109, Transonic Systems). Qb was recorded as flow generated by the arteriovenous pressure gradient. The arteriovenous pressure gradient across the gas exchanger was calculated based on the difference between the inlet (P in) and outlet (P out) pressures. Sweep gas flow (Qg, 100% O 2 ) was controlled by an in-line regulator and set at 1.5-2.0 times Qb. CO 2 removal by the device was calculated as the product of Qg, and its exhaust CO 2 concentration was measured by a CO 2 SMO respiratory profile monitor (Novametrix Medical System, Inc., Wallingford, CT). Pre-and postdevice blood gases were measured with a blood gas system (System BG3 and Co-Oxymeter 482, Instrumentation Laboratory, Lexington, MA). The sheep received constant cage-side care and free access to food and water for the duration of the studies (up to 24 hours).
Results

Arteriovenous Loop Flow Studies
All sheep maintained hemodynamic stability without requiring inotropic or vasopressor drugs. Results are summarized in Figure 2 . Qb was 100 -150 ml/min with the 14 gauge dialysis needles, and 300 ml/min with 12 F arterial and venous cannulas. Increasing to a 15 F outflow cannula did not increase flow. Qb increased to 900 ml/min when the inflow cannula was advanced into the artery (creating a ram effect and directing Qb directly into the cannula). A 6 mm loop transected end on allowed 500 -900 ml/min flow, and an 8-mm loop yielded Qb up to 2 L/min. Qb did not change perceptibly whether the access was connected to a commercially available micropore hollow-fiber gas exchanger (Affinity, AVECOR, Minneapolis, MN), the low-resistance prototype Ambulatory-AVCO 2 R device, or unobstructed 1/4 inch tubing without a gas exchanger. Therefore, Qb was limited by the diameter and length of tubing and not by the gas exchanger.
Ambulatory-AVCO 2 R Prototype Performance
Once we determined optimal inflow technique (8 mm graft, transected and connected end on), we tested our prototype Ambulatory-AVCO 2 R device in five sheep. The mean blood pressure gradient across the Ambulatory-AVCO 2 R gas exchanger at 1 L of flow was only 2.8 Ϯ 0.8 mm Hg. The Ambulatory-AVCO 2 R prototype provided an average CO 2 removal of 104.8 Ϯ 14.0 ml/min in the normal sheep for up to 24 hours at a constant Qb of 900 ml/min with a sweep gas rate of 2 L/min. Arterial pCO 2 remained at 40 -45 mm Hg. Sheep hemodynamics (heart rate, mean arterial pressure, mean pulmonary artery pressure, and cardiac output) remained within normal limits throughout the study. Three animals were allowed to recover from sedation, stand in their cages, eat, and drink. No bleeding, cannula-related, or Ambulatory-AVCO 2 R device complications (leakage, thrombosis, or failure) were seen over the 24 hour study period.
Discussion
In the United States, 15-17 million people have COPD. Because of the large reserves in human lung function and because COPD is a slowly progressive disease, the clinical diagnosis of COPD is often delayed until extensive and irreparable damage has occurred. As COPD progresses, CO 2 retention is a common and grave sign because of a raised equilibrium level between the extra work of breathing (producing more CO 2 ) and decreased ventilation (and therefore decreased CO 2 removal) caused by small airway closure. 15 When COPD reaches end stage, few treatment options are available. Lung volume reduction surgery (LVRS) remains investigational, with limited application and varying intermediate-term results. 16 Several contraindications to LVRS exist, including pulmonary hypertension and hypoxia. Lung transplantation is a practical option for only a small fraction of patients, with only 800 -900 lung transplants performed in the United States annually 17 because of the scarcity of suitable lung donors. Roughly 50% of lung transplants are for COPD, whereas other diseases (cystic fibrosis, bronchiectasis, pulmonary fibrosis, Eisenmenger's syndrome) comprise the remainder. Most patients with end-stage COPD are never evaluated for lung transplantation or fail an evaluation because of concomitant medical problems such as coronary artery disease, severe osteoporosis, cachexia, and peripheral muscle deconditioning and immobility. An artificial lung, which is years away from clinical trials, is invasive and should be reserved for the sickest patients as a bridge to transplant or possibly as a bridge to recovery after acute lung injury. 18, 19 An alternative to transplant for end-stage COPD is needed. Ambulatory AVCO 2 R provides a key opportunity in the treatment of COPD with the uncoupling of CO 2 removal from oxygenation. Hypercarbia, and not hypoxia, often limits COPD patients' ability to exercise. Although hypoxemia may be readily treated with supplemental oxygen, there are limited means for treating hypercarbia. The development of hypercarbia in advanced COPD is the result of increased dead space (Vd/Vt), inspiratory muscle weakness, and a rapid-shallow respiratory pattern. 20 Respiratory muscle weakness contributes to exercise intolerance, deconditioning, and hypercarbia. The work of breathing, normally about 2% of one's overall energy expenditure, can rise up to 50% in end-stage COPD, leading to a state of chronic respiratory weakness. 21 Begin and Grassino 22 reported that chronic hypoventilation was likely to develop in patients with COPD who have a high inspiratory muscle load and inspiratory muscle weakness. In addition, muscle dysfunction may be caused by chronic inactivity, systemic steroids, systemic inflammation, and nutritional imbalance. 23 Peripheral muscle atrophy is not simply a matter of inadequate nutrition because increasing caloric load may increase CO 2 production, aggravating CO 2 retention. Ambulatory AVCO 2 R will eliminate CO 2 buildup to allow ambulation despite increased CO 2 production from muscle activity. Longterm ambulatory AVCO 2 R would enable patients with endstage COPD to conserve energy stores and replenish nutrition, allowing for rebuilding of muscle mass. Therefore, we envision three potential advantages from ambulatory AVCO 2 R: 1) rebuild skeletal muscle strength to the point of independent ambulation, 2) serve as a bridge to lung transplant, and 3) serve as palliative therapy for terminal patients.
Animal studies and clinical experience with AVCO 2 R to date have used percutaneous cannulae for ease of access. Arterial cannula at a size of 12 F and venous cannula at a size of 15 F provide adequate flow in both sheep and humans (approximately 1 L/min flow). However, percutaneous cannulation of arteries and veins is inherently unstable and nonambulatory because the catheters are not secured to the vessel, only to the skin. In our experience, obesity, leg movement, and suture breakage have all contributed to catheter dislodgement. Ventricular assist device experience has shown that long-term transcutaneous access using textured, tunneled cannulae works for many months with mild and usually manageable infectious complications. Ideally, for ambulatory AVCO 2 R, insertion and removal of vascular access should be straightforward, with no major body cavity entry. Access should be available for intermittent or continuous CO 2 removal depending upon clinical need. Intermittent ambulatory AVCO 2 R Figure 2 . Blood flow in parallel to the sheep cranial circulation using 6 mm and 8 mm polytetrafluoroethylene (PTFE) loops accessed by way of 14 gauge dialysis needles, 12 F (arterial) and 15 F (venous) cannulae inserted into the loops, and 6 mm and 8 mm loops. Blood flow did not appreciably change whether the blood was sent through a commercially available low resistance gas exchanger (Affinity, AVECOR, Minneapolis, MN), the prototype low resistance Ambulatory-AVCO 2 R device (MC3 Corp.), or simply through 1/4 inch tubing.
would use a quick connect in the exposed portion of the arteriovenous loop. The quick connect could be designed to restrict flow through the loop, if necessary, to avoid highoutput left ventricular failure.
Oxygenator (gas exchanger) sweep gas is traditionally provided by wall source oxygen or by compressed oxygen tanks. Because ambulatory AVCO 2 R requires only CO 2 removal, the sweep gas can be room air provided by a small air compressor or fan. For this study, the sweep gas:Qb ratio was kept at 2:1, but preliminary studies in our laboratory suggest that higher sweep gas rates (up to 10:1) with resultant very low exit blood pCO 2 may be well tolerated. A higher sweep gas:Qb ratio could provide effective CO 2 removal from a 6 mm loop access (standard dialysis-sized arteriovenous loop).
In these 20 -45 kg sheep, an 8 mm Gore-Tex reinforced graft loop was well tolerated hemodynamically and supplied ample Qb (with reserve capacity) to achieve near total CO 2 removal with our new ultra low resistance Ambulatory-AVCO 2 R device. In conclusion, our studies show that long-term ambulatory AVCO 2 R using a tunneled arteriovenous graft is feasible. When development is complete, ambulatory AVCO 2 R could decrease work of breathing to treat patients with end-stage COPD and CO 2 retention.
